Awakn Life Sciences Appoints Kevin Lorenz as U.S. Head of Commercial Development
Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that the Company has appointed Kevin Lorenz as their U.S. Head of Commercial Development, effective immediately. Mr. Lorenz will lead Awakn's therapeutics commercialization activities in the United States, starting with the launch of its...
2022-03-15 7:30 AM EDT
Awakn Life Sciences to Participate at Upcoming March 2022 Conferences
Toronto, Ontario--(Newsfile Corp. - March 9, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Awakn's Chief Executive Officer, is scheduled to present at the following upcoming March 2022 investor conferences. 34th Annual ROTH Conference Presentation: Sunday, March 13th to Tuesday, March 15th Registration: Click...
2022-03-09 7:30 AM EST
Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules
Toronto, Ontario--(Newsfile Corp. - February 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, strengthened its intellectual property portfolio and pipeline for the treatment of addictions with the filing of a patent application for a new chemical series of entactogen-like molecules. Entactogen-like molecules are a class of psychoactive substances that produce...
2022-02-17 7:30 AM EST
Awakn Life Sciences' Professor Celia Morgan Named One of the Most Influential Women in the Psychedelics Industry
Toronto, Ontario--(Newsfile Corp. - February 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced that Professor Celia Morgan, the Company's Head of Ketamine-Assisted Therapy for Addiction, was named one of Insider's 16 most influential women shaping the future of psychedelics. "We are excited to share this well-deserved recognition for Celia...
2022-02-15 7:30 AM EST
Awakn Life Sciences to Host Fireside Chat with Dr. Ben Sessa, Chief Medical Officer, on March 2nd at 11:00am EST
Toronto, Ontario--(Newsfile Corp. - February 10, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, will host a fireside chat with Dr. Ben Sessa, Chief Medical Officer, on Wednesday, March 2nd at 11:00 a.m. EST. Dr. Sessa, author of 'The Psychedelic Renaissance' amongst other titles, is renowned as one of the most influential figures in the psychedelic...
2022-02-10 7:30 AM EST
Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions
Toronto, Ontario--(Newsfile Corp. - January 26, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announces the filing of a patent application for a new chemical series of entactogen-like molecules, further strengthening Awakn's intellectual property portfolio and pipeline for the treatment of a broad range of addictions including, but not limited to...
2022-01-26 7:30 AM EST
Awakn Life Sciences Signs MOU with Maps
Toronto, Ontario--(Newsfile Corp. - January 19, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today it has signed a Memorandum of Understanding ("MOU") with the Multidisciplinary Association for Psychedelic Studies (MAPS) to explore a partnership to utilize MDMA-assisted therapy to treat Alcohol Use Disorder (AUD) in Europe....
2022-01-19 7:30 AM EST
Awakn Responds to OTC Markets Request on Recent Promotional Activity
Toronto, Ontario--(Newsfile Corp. - January 14, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announces that it has been requested by OTC Markets Group Inc. ("OTC Markets") to issue this statement about certain promotional activity concerning its common stock. On Wednesday, January 12, 2022, OTC Markets informed the Company that it...
2022-01-14 6:00 PM EST
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Toronto, Ontario--(Newsfile Corp. - January 11, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, is delighted to announce ground-breaking positive data from their Phase II A/B trial. It was the first controlled trial in the world to investigate Ketamine-Assisted Therapy for the treatment of Alcohol Use Disorder (AUD), the results have been...
2022-01-11 7:30 AM EST
Awakn Life Sciences Expands World's First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral Addictions
Toronto, Ontario--(Newsfile Corp. - January 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn), a biotechnology company developing and delivering psychedelic medicines to better treat addiction, announced today that it has received ethical committee approval to expand its existing ketamine study beyond Gambling Disorder to include three other behavioral addictions including Binge Eating Disorder, Compulsive Sexual Behaviour and Internet Gaming Disorder. The...
2022-01-05 7:30 AM EST
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders
Toronto, Ontario--(Newsfile Corp. - January 4, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced that management, the Board of Directors ("the Board") and key shareholders (the "Lock-up Shareholders") have voluntarily entered into a Lock-up Agreement extension of their equity ownership with respect to approximately 11,500,000...
2022-01-04 8:28 AM EST
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights
Toronto, Ontario--(Newsfile Corp. - December 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, today is reporting its financial results and business highlights for the three and nine months ended October 31, 2021. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise...
2021-12-15 7:30 AM EST
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors
Toronto, Ontario--(Newsfile Corp. - December 14, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the appointment of Paul Carter, former Chief Commercial Officer of Gilead Sciences Inc., as an independent member of its Board of Directors, increasing the independent majority on the board. Mr. Carter will be replacing Dr....
2021-12-14 7:30 AM EST
Awakn Life Sciences to Participate at Upcoming December Conferences
Toronto, Ontario--(Newsfile Corp. - December 3, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, is scheduled to present at the following upcoming virtual December investor conferences. H.C. Wainwright 2nd Annual Psychedelics Conference Presentation: On Demand Beginning Monday,...
2021-12-03 7:30 AM EST
Awakn Life Sciences Strengthens Executive Leadership Team
Toronto, Ontario--(Newsfile Corp. - November 30, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn' or the 'Company'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the execution of an agreement to appoint Kate Butler as new Chief Financial Officer ("CFO"), and Jonathan Held, current Chief Financial Officer, to transition to Awakn's Chief Business Officer. Under the terms...
2021-11-30 7:30 AM EST
Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK
Toronto, Ontario--(Newsfile Corp. - November 16, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today it has signed a Memorandum of Understanding ("MOU") with Devon Partnership NHS Trust (DPT) and University of Exeter ("UoE"). The partnership establishes a framework and strategic relationship to assess NHS organizational...
2021-11-16 7:43 AM EST
Awakn Life Sciences Announces the Findings from the Phase II A/B Study Are to Be Published in the American Journal of Psychiatry
Toronto, Ontario--(Newsfile Corp. - November 4, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) psychotherapy intervention study, which was the first controlled study in the world to investigate ketamine-assisted psychotherapy, will be published in the...
2021-11-04 7:30 AM EDT
Awakn Life Sciences to Participate at the Wonderland: Miami Conference in November 2021
Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Professor David Nutt, Chief Research Officer of Awakn Life Sciences, and Dr. Ben Sessa, Chief Medical Officer of Awakn Life Sciences, will participate in the Microdose Presents: Wonderland, Miami Conference in-person from...
2021-11-02 7:30 AM EDT
Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program
Toronto, Ontario--(Newsfile Corp. - October 28, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the success of phase one of its new chemical entity (NCE) development program to strengthen Awakn's pipeline for the treatment of a broad range of both substance and behavioral addictions. Novel MDMA-like NCE chemical series have...
2021-10-28 7:30 AM EDT
Awakn Life Sciences to Present at the Benzinga Global Small Cap Conference
Toronto, Ontario--(Newsfile Corp. - October 22, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Chief Executive Officer, Anthony Tennyson, will present a corporate overview at the Benzinga Global Small Cap Conference, which is being held virtually on October 27 - 28, 2021. Mr. Tennyson will deliver his presentation on...
2021-10-22 9:00 AM EDT